Real-world treatment landscape and clinical outcomes in first-line advanced or metastatic gastroesophageal adenocarcinoma in the United States
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag350 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Jin Gu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Foster City, CA 94404, United States. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Adenocarcinoma, Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences, Inc.
Abstract (Originalsprache)
Background
Contemporary real-world evidence in advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma (GC/GEJC/EAC) remains limited. This study evaluated real-world treatment patterns and clinical outcomes in patients with advanced GC/GEJC/EAC treated with first-line therapy in the United States. Patients and methods Treatment patterns were assessed in adults from the Flatiron database with advanced or metastatic HER2-negative GC/GEJC/EAC who initiated first-line treatment between May 1, 2021, and July 31, 2025 (overall cohort). Clinical outcomes were assessed using the Kaplan–Meier method in a subcohort with ≥6 months of follow‑up.
Results
Among 2340 eligible patients, the most common first-line regimen was IO+FOLFOX/CAPOX (31.6%). This regimen was used in 47.6% of patients with programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 1 expression. Starting in 2024, zolbetuximab+FOLFOX/CAPOX was administered more frequently in patients with CPS <1 vs ≥1 (6.1% vs 1.9%) and CPS <5 vs ≥5 (4.6% vs 0.8%) expression. In the subcohort (n = 2117), IO+FOLFOX/CAPOX vs FOLFOX/CAPOX was associated with significantly longer median (months; hazard ratio [95% CI]) real-world overall survival (12.3 vs 11.3; 0.81 [0.69-0.94]), time to next treatment or death (8.0 vs 6.1; 0.64 [0.55-0.75]), and time to treatment discontinuation (6.0 vs 3.0; 0.54 [0.47-0.63]). Differences in outcomes were driven by patients with CPS ≥1 expression, with no differences in patients with CPS <1 expression.
Conclusions
IO+FOLFOX/CAPOX was the most frequent first-line regimen in advanced or metastatic GC/GEJC/EAC and showed improved real-world outcomes vs FOLFOX/CAPOX. Despite these gains, overall survival remains poor, underscoring unmet needs and the importance of biomarker-informed treatment selection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gilead Sciences, Foster City, CA 94404, United States.
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
ORCID-Profile: Jin Gu
Förderung
- Gilead Sciences, Inc
Zitieren
APA
Gu, J., Mhatre, S. K., Koralek, D. O., Gupta, R., & Ajani, J. A. (2026). Real-world treatment landscape and clinical outcomes in first-line advanced or metastatic gastroesophageal adenocarcinoma in the United States. The Oncologist. https://doi.org/10.1093/oncolo/oyag350
Vancouver
Gu J, Mhatre SK, Koralek DO, Gupta R, Ajani JA. Real-world treatment landscape and clinical outcomes in first-line advanced or metastatic gastroesophageal adenocarcinoma in the United States. The Oncologist. 2026. doi:10.1093/oncolo/oyag350
BibTeX
@article{Gu2026,
author = {Gu, Jin and Mhatre, Shivani K and Koralek, Daniel O and Gupta, Ravindra and Ajani, Jaffer A},
title = {Real-world treatment landscape and clinical outcomes in first-line advanced or metastatic gastroesophageal adenocarcinoma in the United States},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag350}
}
EUVIMED